Update from the Chordoma Foundation January 2017

MAB recommends clinical trials for patients with recurrent or advanced chordoma

Historically, treatment options for patients with recurrent or advanced chordoma have been limited and inadequate. However, as we’ve learned more about the biology of the disease and its vulnerabilities, new and more promising treatment options have begun to emerge.
Prompted by these developments, our Medical Advisory Board (MAB) recently recommended a new treatment pathway for patients with advanced or recurrent chordoma; one that prioritizes clinical trial participation to gain access to cutting edge therapies that could be more effective than standard treatments.

To help chordoma patients more easily find and access relevant clinical trials, last week we re-launched the Clinical Trials page on our website. It now includes straightforward explanations of clinical trials designed specifically for chordoma patients, as well as eight other relevant clinical trials recommended by our MAB that are currently open to chordoma patients.

Read more about this new treatment pathway, and clinical trials open to chordoma patients »

More clinical trials are on the way

In addition to the clinical trials currently open to chordoma patients, we are supporting a series of upcoming clinical trials testing promising new treatment approaches. Check out our Clinical Trials Program to learn more about the pipeline of trials we’re supporting and how we’re working to eliminate the barriers that typically hinder trials for rare cancers. Our goal is to launch at least 10 clinical trials by 2020.


The unsung heroes behind new chordoma models

Through their quiet, unflappable persistence, Clinical Research Director Benita Valappil of the University of Pittsburgh Medical Center and nurse Roberta Sales of Memorial Sloan Kettering Cancer Center – our tumor donation program’s first two institutional partners – have dramatically increased chordoma tissue donation and enabled the creation of new chordoma models that are fueling drug discovery.

Read Benita and Roberta's Featured Researcher profile »


Teaming up to advance cutting edge chordoma research in Canada

Edward Les and Steven Golick, the architects behind the Foundation’s new partnership with the Canadian Cancer Society (CCS), have been tireless champions for chordoma research. Thanks to their efforts to expand Canada’s involvement in the search for a cure, Canadian donors can now make tax-deductible gifts in support of high-impact, in-country chordoma research. “I would say I have an attitude of gratitude,” notes Ed. “Many people, myself included, have lived substantially longer and with a substantially higher quality of life, thanks to the efforts of the Chordoma Foundation. I feel it is my privilege – and my pleasure – to pay it forward.”

Read Ed and Steven's Featured Champion profile »


Second Annual Brooklyn Half Marathon – May 20, 2017

Thanks to the runners who signed up to join Team Chordoma and captain Steven Mandel at the Airbnb Brooklyn Half Marathon on May 20!
Not running? Mark your calendars to come out and support the team – and chordoma research – at a post-run celebration. More details to follow.   

Support CF by shopping at Amazon Smile this Valentine's Day

Planning to pick up a valentines gift? Buy it at and Amazon will donate a portion of your purchase to the Chordoma Foundation.

Just signup and choose CF as your designated charity.


Copyright © 2017 Chordoma Foundation, All rights reserved.

unsubscribe from this list    update subscription preferences